Zidesamtinib Demonstrates 93% Response Rate in TKI-Naive Patients With Advanced ROS1-Positive NSCLC

Phase 2positiveZidesamtinibPositive

AI Analysis

Summary

Zidesamtinib demonstrated a 93% response rate in TKI-naive patients with advanced ROS1-positive NSCLC in the Phase I/II ARROS-1 trial, with notably high intracranial activity including 100% intracranial response rate and 70% intracranial complete response rate.

Clinical Trial Data

Phase

Phase I/II

Primary Endpoint

Met

Outcome Details

93% response rate in TKI-naive patients; 100% intracranial response rate; 70% intracranial complete response rate

Importance:7/10

Sentiment:

0.85

oncologyNSCLCROS1-positiveclinical trial dataresponse rateintracranial activity

Related Companies

$GBCYD

Read the original article

Published by PR Newswire Biotech on September 14, 2026 12:18 PM

Read Original